Development and validation of a score to assess risk of adverse drug reactions among in-hospital patients 65 years or older: the GerontoNet ADR risk score.
about
Hospitalization in older patients due to adverse drug reactions -the need for a prediction toolAsthma in the elderly: a different disease?Predicting risk of adverse drug reactions in older adultsPredicting adverse drug reactions in older adults; a systematic review of the risk prediction modelsRisk Factors Associated with the Requirement for Pharmaceutical Intervention in the Hospital Setting: A Systematic Review of the LiteratureAdverse drug reactions related hospital admissions in persons aged 60 years and over, The Netherlands, 1981-2007: less rapid increase, different drugsInappropriate drugs in elderly patients with severe cognitive impairment: results from the shelter studyDevelopment of an adverse drug reaction risk assessment score among hospitalized patients with chronic kidney diseaseDevelopment and validation of a risk model for predicting adverse drug reactions in older people during hospital stay: Brighton Adverse Drug Reactions Risk (BADRI) modelPrediction of Hospitalization due to Adverse Drug Reactions in Elderly Community-Dwelling Patients (The PADR-EC Score)Challenges in the pharmacological treatment of geriatric asthma.Primary care providers' perspective on prescribing opioids to older adults with chronic non-cancer pain: a qualitative studyAnalysis of risk factors for adverse drug events in critically ill patients*.Current and future perspectives on the management of polypharmacy.Predictors of rehospitalization among elderly patients admitted to a rehabilitation hospital: the role of polypharmacy, functional status, and length of stay.Impact of prescribed medications on patient safety in older people.Risk of thiazide-induced metabolic adverse events in older adults.Utilization of potentially inappropriate medications in elderly patients in a tertiary care teaching hospital in India.Multiple drug intolerance syndrome: a large-scale retrospective study.A clinical adverse drug reaction prediction model for patients with chagas disease treated with benznidazoleDo geriatric conditions increase risk of adverse drug reactions in ambulatory elders? Results from the VA GEM Drug StudyPatient risk factors for developing a drug-related problem in a cardiology ward.Geriatric conditions, medication use, and risk of adverse drug events in a predominantly male, older veteran population.Determination of risk factors for drug-related problems: a multidisciplinary triangulation process.Impaired cerebral autoregulation is associated with vasospasm and delayed cerebral ischemia in subarachnoid hemorrhage.Protocol for a Prospective (P) study to develop a model to stratify the risk (RI) of medication (M) related harm in hospitalized elderly (E) patients in the UK (The PRIME study).Intervention to Improve Appropriate Prescribing and Reduce Polypharmacy in Elderly Patients Admitted to an Internal Medicine Unit.Year in review: medication mishaps in the elderly.Improving medication safety: Development and impact of a multivariate model-based strategy to target high-risk patients.The Burden of Polypharmacy in Patients Near the End of LifeHow healthy is community-dwelling elderly population? Results from Southern Italy.Vitamin D deficiency as adverse drug reaction? A cross-sectional study in Dutch geriatric outpatients.Making hospitals safer for older adults: updating quality metrics by understanding hospital-acquired delirium and its link to falls.Predictive Factors of Rapid Cognitive Decline in Patients with Alzheimer Disease.Regional differences in prescribing quality among elder veterans and the impact of rural residence.Risk factors for developing drug-related problems in patients with cardiovascular diseases attending Gondar University Hospital, Ethiopia.Preventable and non-preventable adverse drug events in hospitalized patients: a prospective chart review in the Netherlands.Inappropriate prescribing: criteria, detection and prevention.Adverse drug reactions in older people: detection and prevention.Determining the frequency and preventability of adverse drug reaction-related admissions to an Irish University Hospital: a cross-sectional study.
P2860
Q26748526-22648AB6-A243-411A-A39B-7BFBB5BE20ADQ26750425-F4D15F92-CCAC-4A5D-A1A6-255663D04960Q26770379-822931AE-C32C-4232-9432-BF49AB4945C1Q27006081-BA27E8A9-F707-4560-AC75-F09786809E80Q28075471-53FC578E-D92D-427D-A7D1-F88DCC36D47FQ28476135-3FA54E21-A575-401A-8772-8E63107D78A0Q28484216-5A2FEDD0-D485-41FE-87F1-82DB37CF46A9Q28538142-E4CEBAB1-8972-4F3E-9966-E8FB31D32202Q28544629-113B0BB9-5DDD-43B4-96FB-3AA67DBB5485Q28553063-5D4506C8-0838-4671-967D-293B8AFD60D6Q30251770-FC38393C-180F-4F7C-B57B-E4D541F7F476Q31022925-D07BE980-56B1-44EC-8510-E96B9298E6E4Q33397860-9E2F1559-E02B-4050-B968-91687467ECA7Q33454888-252CA604-D875-4EF2-833A-A8B0DA3DD4FCQ33910972-5B32FE96-0435-4722-B13F-FA4019CB3BFEQ33949432-51049CF9-0612-4813-A9E1-75E6CD1307D9Q34026623-DB896C5E-6B03-4432-AA8F-36E4F2347ABAQ34221335-84E816D1-2A87-448A-BC00-016A113C7B3AQ34567477-0E01E2E5-5B9D-49AF-8184-A057FA21E7AEQ34596630-7B92C0BA-F4D2-4027-A642-5DC164331229Q34660345-8C2EFB6A-E26E-431E-8606-AA07B9C9EABFQ34764219-094166AC-2EF6-4A0A-ABD5-9670ECC4BD2CQ35014979-2F4F9333-0EC2-4125-9F1E-750C2327BD2FQ35203964-19913D33-1A8D-4838-933A-42A017A4B194Q35556734-7E676706-C6F2-41B6-A12C-EB0BE176AF0AQ35898547-090F8637-EEE0-44B2-9ED1-93144401BCC2Q36208058-510539AD-AD23-41EC-9641-AE2776859C21Q36278264-54B13C75-BA82-4F23-997A-2790631710C3Q36278782-979300CF-8CB0-4539-A4EC-8076E2D2D116Q36522682-8248072E-7A01-4B78-AE16-1F0BC154C6E0Q36738492-87C3458E-3CB8-4F7D-B0E6-6F139F932CA1Q36805116-3ECF10C7-FB5F-4482-956A-5A41F734AA3FQ37372396-2FD13BEC-0381-470D-A47A-4189F229E634Q37562863-BCE5397A-DBB2-492C-8144-10EAF3ABCF47Q37613572-15E64119-EDA7-408B-9D09-1A029DE1BB61Q37649551-FD2E9722-1048-42C3-8433-883DDE803778Q37943437-D63904A2-C728-4C1D-9EEF-DFDDB627AEECQ38014123-3392123A-D359-4639-8936-AA83FAD45B5FQ38014124-FD9585A7-1B60-4C28-A332-9B0E4291259DQ38079775-3D6A4E24-AAA9-4B99-9F11-6CC61732CE0B
P2860
Development and validation of a score to assess risk of adverse drug reactions among in-hospital patients 65 years or older: the GerontoNet ADR risk score.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Development and validation of ...... the GerontoNet ADR risk score.
@en
Development and validation of ...... the GerontoNet ADR risk score.
@nl
type
label
Development and validation of ...... the GerontoNet ADR risk score.
@en
Development and validation of ...... the GerontoNet ADR risk score.
@nl
prefLabel
Development and validation of ...... the GerontoNet ADR risk score.
@en
Development and validation of ...... the GerontoNet ADR risk score.
@nl
P2093
P1476
Development and validation of ...... the GerontoNet ADR risk score
@en
P2093
Annemie Somers
Chakravarthi Rajkumar
Graziano Onder
Marieke C Meinardi
Mirko Petrovic
Tischa J M van der Cammen
Winih P Markito-Notenboom
P304
P356
10.1001/ARCHINTERNMED.2010.153
P407
P577
2010-07-01T00:00:00Z